Page 1986 - Williams Hematology ( PDFDrive )

1960 Part XII: Hemostasis and Thrombosis Chapter 114: Control of Coagulation Reactions 1961

defects in bleeding or thrombosis has been confirmed for this inhibitor. 32. Jhingan A, Zhang L, Christiansen WT, Castellino FJ: The activities of recombinant
In purified reaction mixtures, protein C inhibitor also efficiently neu- gamma-carboxyglutamic-acid-deficient mutants of activated human protein C toward
tralizes thrombin in the presence of thrombomodulin, although no human coagulation factor Va and factor VIII in purified systems and in plasma.
359
Biochemistry 33(7):1869–1875, 1994.
studies show that this is a physiologic reaction or that it is associated 33. Regan LM, Mollica JS, Rezaie AR, Esmon CT: The interaction between the endothelial
with thrombosis. cell protein C receptor and protein C is dictated by the gamma-carboxyglutamic acid
domain of protein C. J Biol Chem 272(42):26279–26284, 1997.
34. Greengard JS, Fisher CL, Villoutreix B, Griffin JH: Structural basis for type I and type II
deficiencies of antithrombotic plasma protein C: Patterns revealed by three-dimensional
REFERENCES molecular modelling of mutations of the protease domain. Proteins 18(4):367–380, 1994.
35. Gale AJ, Heeb MJ, Griffin JH: The autolysis loop of activated protein C interacts with
1. MacFarlane RG: An enzyme cascade in the blood clotting mechanism and its function factor Va and differentiates between the Arg506 and Arg306 cleavage sites. Blood
as a biochemical amplifier. Nature 202:498–499, 1964. 96(2):585–593, 2000.
2. Davie EW, Ratnoff OD: Waterfall sequence for intrinsic blood clotting. Science 36. Friedrich U, Nicolaes GAF, Villoutreix BO, Dahlbäck B: Secondary substrate-binding
145(3638):1310–1312, 1964. exosite in the serine protease domain of activated protein C important for cleavage at
3. Furie B, Furie BC: Mechanisms of thrombus formation. N Engl J Med 359(9):938–949, Arg-506 but not at Arg-306 in factor Va. J Biol Chem 276(25):23105–23108, 2001.
2008. 37. Rezaie AR: Exosite-dependent regulation of the protein C anticoagulant pathway.
4. Lammle B, Griffin JH: Formation of the fibrin clot: The balance of procoagulant and Trends Cardiovasc Med 13(1):8–15, 2003.
inhibitory factors. Clin Haematol 14(2):281–342, 1985. 38. Gale AJ, Griffin JH: Characterization of a thrombomodulin binding site on protein
5. van de Wouwer M, Collen D, Conway EM: Thrombomodulin-protein C-EPCR system: C and its comparison to an activated protein C binding site for factor Va. Proteins
Integrated to regulate coagulation and inflammation. Arterioscler Thromb Vasc Biol 54(3):433–441, 2004.
24(8):1374–1383, 2004. 39. Gale AJ, Tsavaler A, Griffin JH: Molecular characterization of an extended binding site
6. Griffin JH: The thrombin paradox. Nature 378(6555):337–338, 1995. for coagulation factor Va in the positive exosite of activated protein C. J Biol Chem
7. Mosnier LO, Zlokovic BV, Griffin JH: The cytoprotective protein C pathway. Blood 277(32):28836–28840, 2002.
109(8):3161–3172, 2007. 40. Mosnier LO, Gale AJ, Yegneswaran S, Griffin JH: Activated protein C variants with nor-
8. Griffin JH, Zlokovic BV, Mosnier LO: Activated protein C: Biased for translation. Blood mal cytoprotective but reduced anticoagulant activity. Blood 104(6):1740–1745, 2004.
125(19):2898–2907, 2015. 41. Mosnier LO, Yang XV, Griffin JH: Activated protein C mutant with minimal antico-
9. Fukudome K, Esmon CT: Identification, cloning, and regulation of a novel endothelial agulant activity, normal cytoprotective activity, and preservation of thrombin activ-
cell protein C/activated protein C receptor. J Biol Chem 269(42):26486–26491, 1994. able fibrinolysis inhibitor-dependent cytoprotective functions. J Biol Chem 282(45):
10. Rao LV, Esmon CT, Pendurthi UR: Endothelial cell protein C receptor: A multiliganded 33022–33033, 2007.
and multifunctional receptor. Blood 124(10):1553–1562, 2014. 42. Mosnier LO, Zampolli A, Kerschen EJ, et al: Hyper-antithrombotic, non-cytoprotective
11. Heeb MJ, Mesters RM, Tans G, et al: Binding of protein S to factor Va associated with Glu149Ala-activated protein C mutant. Blood 113(23):5970–5978, 2009.
inhibition of prothrombinase that is independent of activated protein C. J Biol Chem 43. Bae JS, Yang L, Manithody C, Rezaie AR: Engineering a disulfide bond to stabilize the
268(4):2872–2877, 1993. calcium-binding loop of activated protein C eliminates its anticoagulant but not its pro-
12. Heeb MJ, Rosing J, Bakker HM, et al: Protein S binds to and inhibits factor Xa. Proc Natl tective signaling properties. J Biol Chem 282(12):9251–9259, 2007.
Acad Sci U S A 91(7):2728–2732, 1994. 44. Yang L, Bae JS, Manithody C, Rezaie AR: Identification of a specific exosite on acti-
13. Hackeng TM, van ‘t Veer C, Meijers JC, Bouma BN: Human protein S inhibits proth- vated protein C for interaction with protease activated receptor 1. J Biol Chem 282(35):
rombinase complex activity on endothelial cells and platelets via direct interactions 25493–25500, 2007.
with factors Va and Xa. J Biol Chem 269(33):21051–21058, 1994. 45. Dreyfus M, Magny JF, Bridey F, et al: Treatment of homozygous protein C deficiency
14. Morrissey JH, Macik BG, Neuenschwander PF, Comp PC: Quantitation of activated and neonatal purpura fulminans with a purified protein C concentrate. N Engl J Med
factor VII levels in plasma using a tissue factor mutant selectively deficient in promot- 325(22):1565–1568, 1991.
ing factor VII activation. Blood 81(3):734–744, 1993. 46. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recombinant human
15. Gruber A, Griffin JH: Direct detection of activated protein C in blood from human activated protein C for severe sepsis. N Engl J Med 344(10):699–709, 2001.
subjects. Blood 79(9):2340–2348, 1992. 47. Gruber A, Griffin JH, Harker LA, Hanson SR: Inhibition of platelet-dependent thrombus
16. Nossel HL, Yudelman I, Canfield RE, et al: Measurement of fibrinopeptide A in human formation by human activated protein C in a primate model. Blood 73(3):639–642, 1989.
blood. J Clin Invest 54(1):43–53, 1974. 48. Taylor FB Jr, Chang AC, Esmon CT, et al: Protein C prevents the coagulopathic and lethal
17. Nossel HL: Radioimmunoassay of fibrinopeptides in relation to intravascular coagula- effects of Escherichia coli infusion in the baboon. J Clin Invest 79(3):918–925, 1987.
tion and thrombosis. N Engl J Med 295(8):428–432, 1976. 49. Ranieri VM, Thompson BT, Barie PS, et al: Drotrecogin Alfa (Activated) in Adults with
18. Bauer KA, Rosenberg RD: The pathophysiology of the prethrombotic state in humans: Septic Shock. N Engl J Med 366(22):2055–2064, 2012.
Insight gained from studies using markers of hemostatic system activation. Blood 50. Kalil AC, LaRosa SP: Effectiveness and safety of drotrecogin alfa (activated) for severe
70(2):343–350, 1987. sepsis: A meta-analysis and metaregression. Lancet Infect Dis 12(9):678–686, 2012.
19. Bauer KA, Kass BL, ten Cate H, et al: Detection of factor X activation in humans. Blood 51. Christiaans SC, Wagener BM, Esmon CT, Pittet JF: Protein C and acute inflammation: A
74(6):2007–2015, 1989. Clinical and biologic perspective. Am J Physiol Lung Cell Mol Physiol 305(7):L455–L466,
20. Bauer KA, Kass BL, ten Cate H, et al: Factor IX is activated in vivo by the tissue factor 2013.
mechanism. Blood 76(4):731–736, 1990. 52. Foster DC, Yoshitake S, Davie EW: The nucleotide sequence of the gene for human
21. Jesty J, Beltrami E, Willems G: Mathematical analysis of a proteolytic positive-feedback protein C. Proc Natl Acad Sci U S A 82(14):4673–4677, 2013.
loop: Dependence of lag time and enzyme yields on the initial conditions and kinetic 53. D’Ursi P, Marino F, Caprera A, et al: ProCMD: A database and 3D web resource for
parameters. Biochemistry 32(24):6266–6274, 1993. protein C mutants. BMC Bioinformatics 8(Suppl 1):S11, 2007.
22. Beltrami E, Jesty J: Mathematical analysis of activation thresholds in enzyme-catalyzed 54. Saunders RE, Perkins SJ: CoagMDB: A database analysis of missense mutations within
positive feedbacks: Application to the feedbacks of blood coagulation. Proc Natl Acad four conserved domains in five vitamin K-dependent coagulation serine proteases
Sci U S A 92(19):8744–8748, 1995. using a text-mining tool. Hum Mutat 29(3):333–344, 2008.
23. Nicolaes GAF, Dahlbäck B: Factor V and thrombotic disease: Description of a Janus- 55. Greengard JS, Griffin JH, Fisher CL: Possible structural implications of 20 mutations in
faced protein. Arterioscler Thromb Vasc Biol 22(4):530–538, 2002. the protein C protease domain. Thromb Haemost 72(6):869–873, 1994.
24. Stenflo J: A new vitamin K-dependent protein. Purification from bovine plasma and 56. Rovida E, Merati G, D’Ursi P, et al: Identification and computationally-based struc-
preliminary characterization. J Biol Chem 251(2):355–363, 1976. tural interpretation of naturally occurring variants of human protein C. Hum Mutat
25. Seegers WH, Novoa E, Henry RL, Hassouna HI: Relationship of “new” vitamin K- 28(4):345–355, 2007.
dependent protein C and “old” autoprothrombin II-a. Thromb Res 8(5):543–552, 1976. 57. Yin T, Miyata T: Dysfunction of protein C anticoagulant system, main genetic risk fac-
26. Kisiel W: Human plasma protein C: Isolation, characterization, and mechanism of acti- tor for venous thromboembolism in northeast Asians. J Thromb Thrombolysis 37(1):
vation by alpha-thrombin. J Clin Invest 64(3):761–769, 1979. 56–65, 2014.
27. Foster DC, Davie EW: Characterization of a cDNA coding for human protein C. Proc 58. Tang L, Lu X, Yu JM, et al: PROC c.574_576del polymorphism: A common genetic
Natl Acad Sci U S A 81(15):4766–4770, 1984. risk factor for venous thrombosis in the Chinese population. J Thromb Haemost
28. Beckmann RJ, Schmidt RJ, Santerre RF, et al: The structure and evolution of a 461 10(10):2019–2026, 2012.
amino acid human protein C precursor and its messenger RNA, based upon the DNA 59. Ding Q, Yang L, Hassanian SM, Rezaie AR: Expression and functional characterisation
sequence of cloned human liver cDNAs. Nucleic Acids Res 13(14):5233–5247, 1985. of natural R147W and K150del variants of protein C in the Chinese population. Thromb
29. Griffin JH, Evatt B, Zimmerman TS, et al: Deficiency of protein C in congenital throm- Haemost 109(4):614–624, 2013.
botic disease. J Clin Invest 68(5):1370–1373, 1981. 60. Jalbert LR, Rosen ED, Moons L, et al: Inactivation of the gene for anticoagulant pro-
30. Mather T, Oganessyan V, Hof P, et al: The 2.8 Å crystal structure of Gla-domainless tein C causes lethal perinatal consumptive coagulopathy in mice. J Clin Invest 102(8):
activated protein C. EMBO J 15(24):6822–6831, 1996. 1481–1488, 1998.
31. Kurosawa S, Galvin JB, Esmon NL, Esmon CT: Proteolytic formation and properties of 61. DiScipio RG, Davie EW: Characterization of protein S, a gamma-carboxyglutamic acid
functional domains of thrombomodulin. J Biol Chem 262(5):2206–2212, 1987. containing protein from bovine and human plasma. Biochemistry 18(5):899–904, 1979.

Kaushansky_chapter 114_p1949-1966.indd 1961 9/18/15 10:06 AM